Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand.

Slides:



Advertisements
Similar presentations
Framework for Operations and Implementation Research in Health
Advertisements

A brief overview of ART services at QECH, Malawi Kudzala Aub. MMEDsc. Student Sr. Lead ART Clinician/ HIV Medicine Registrar.
DOTS-Plus to DOTS Philippines Thelma E. Tupasi Tropical Disease Foundation Rosalind G. Vianzon NTP Manager, Philippines.
Scale-up of Programmatic MDR TB Management (PMTM) in the Philippines ROSALIND G. VIANZON, MD, MPH NTP Manager Department of Health Philippines.
Expert consultation on TB/HIV research priorities, February 2005 Mesdames et messieurs, soyez les bienvenus On behalf of the organizing committee.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Key messages Stephen S Lim, et al. Lancet 2007; 370:
Factors Associated with Interruption of Treatment Among Pulmonary Tuberculosis Patients in Plateau State, Nigeria, 2011 Luka M. Ibrahim 1, P. Nguku 1,
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Manila, Dec.2014 NEW DRUGS INTRODUCTION IN VIETNAM – SHORT PROGRESS UPDATE.
Key Terms for Monitoring and Evaluation. Objectives Explain the difference between monitoring and evaluation. Introduce the most common M&E terms. Review.
1 Introduction to Drug-Resistant TB Session 2. USAID TB CARE II PROJECT Classification of drug-resistant TB “Drug-resistant TB” is a general term to describe.
The Global Plan to Stop TB, (1)
African Business Leaders on Health GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 2010 Technical Assistance.
MDR-TB: a fight we cannot afford to lose! Alexander Golubkov, MD, MPH Senior TB Technical Advisor.
RNTCP: DOTS Expansion and plans for DOTS-Plus
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
World Health Organization
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Progress and Plans for PPM in the Western Pacific Region Fifth PPM DOTS Subgroup Meeting Cairo, Egypt.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
The Global Fund- structure, function and evolution February 18, 2008.
Monitoring Drug Resistant Tuberculosis Treatment in Brazil through an Innovative Web-based Information System Dr. Luis Gustavo Bastos Management Sciences.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Programmatic Management of Multidrug Resistant TB (PMDT) 5 th Joint International Monitoring Mission of NTP, Thailand 23 August, 2013.
Public-Private Partnerships -Selected Experiences in the Western Pacific & Cambodia- National Forum on Public-Private Partnership in Health 7 November,
Introduction to Elements of In-Country Drug Management with Focus on TB Drugs Jim Rankin Director, Center for Pharmaceutical Management Management Sciences.
“The causes of Anti-TB medicines shortages in EMR countries and how to avoid them in the future” Khaled Sultan Drug Management Technical Officer, STOP.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
TB/HIV Research Approaches and Challenges Naomi Bock, MD Global AIDS Program Centers for Disease Control and Prevention February 14, 2005.
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
Good Procurement Practices in National TB Programs
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Task Shifting in Malawi around delivery of antiretroviral therapy Anthony D Harries “The Union” Paris, France.
CPM Programs1. 2 Center for Pharmaceutical Management Programs James Rankin.
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
Challenges/barriers for moving forward Ernesto Jaramillo WHO/Stop TB Department Palliative Care and M/XDR-TB November, 2010 Geneve, Switzerland.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Bridging the Research-to-Practice Gap Session 1. Session Objectives  Understand the importance of improving data- informed decision making  Understand.
1 DEWG meeting October 2009 Human Resource Development for TB Control (HRD-TB) Sub Group within the DEWG of the Stop TB Partnership. Wanda Walton.
Principles and Structure of a Research Protocol Anthony Harries The Union, Paris, France.
Quality of Voluntary Medical Male Circumcision Services during Scale-Up: A Comparative Process Evaluation in Kenya, South Africa, Tanzania and Zimbabwe.
Access to anti-TB medicines WHO/EDM Technical briefing seminar for international staff active in pharmaceutical support programmes Salle G, WHO HQ 30.
Exploring financing options NATIONAL TB CONTROL OF VIETNAM.
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
Introducing fixed dose combination tablets into DR CONGO using the Global TB Drug Facility.
Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?
PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
Thirteenth Board Meeting Geneva, April 2006 Report of the Portfolio Committee.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
Palliative Care and M/XDR-TB Global burden of M/XDR-TB
Global Drug Facility An innovative approach to supplying anti-TB drugs
Increased access to quality TB drugs
Expanding ARV treatment in developing countries: Issues and Prospects
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
Stop TB Partnership Secretariat (TBP)
Committee Task Statement (1)
4.2 CLIMATE SERVICES, ACTION AND RESILIENCE
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
TB Strategy & Health Systems (TBS) TB Monitoring & Evaluation (TME)
Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements.
Presentation transcript:

Sources of Limited Access to Treatment High Cost of Treatment Lack of Pilot Projects Lack of Evidence Lack of Policy Lack of Demand

Treatment Regimen Costs HRHRESHRESZK Resistance Pattern Per Patient Drug Cost (USD) Standard Reference Country Cost (USA) High Income Country Average Cost Low Income Country Average Cost Green Light Committee Cost Gupta, et al., Science 2001.

Linking Independent Concepts GLC ACCESS RATIONAL USE POLICY

Green Light Committee (GLC) Releases preferentially-priced, quality-assured drugs Decision process –application review Instructions for Applying to the Green Light Committee for Access to Second-line Anti-TB Drugs Guidelines for Establishing DOTS-Plus Pilot Projects for the Management of MDR-TB –site visit Continual monitoring of projects Technical assistance Gupta, et al. Trop Med Intl Health, 2001

Changing Global Health Policy New guidelines for MDR-TB treatment Expanding DOTS framework to include MDR-TB –HIV, public-private mix Improving allocation of financial resources Increasing new funds for TB control Scaling up primary health care/capacity building Bridging equity gap No longer whether or not to treat patients, but how to best treat patients

Similarities between HIV and MDR-TB Multidrug regimen given for extended periods with adverse events Disproportionately affects disadvantaged Access to drugs Drug resistance Laboratory requirements Lack of standard international policy Most experience in resource-wealthy settings